Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for EIGR, OLPX and VWE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Wednesday, 30 November 2022 10:45 AM

Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / November 30, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

EIGR Shareholders Click Here: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34174&wire=1
OLPX Shareholders Click Here: https://www.zlk.com/pslra-1/olaplex-holdings-lawsuit-submission-form?prid=34174&wire=1
VWE Shareholders Click Here: https://www.zlk.com/pslra-1/vintage-wine-estates-class-action-lawsuit-submission-form?prid=34174&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Wednesday, November 30, 2022, Press release picture

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)

EIGR Lawsuit on behalf of: investors who purchased March 10, 2021 - October 4, 2022
Lead Plaintiff Deadline : January 9, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34174&wire=1

According to the filed complaint, during the class period, Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Olaplex Holdings, Inc. (NASDAQ: OLPX)

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Olaplex common stock pursuant and/or traceable to the Company's initial public offering conducted on or around September 30, 2021.
Lead Plaintiff Deadline : January 17, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/olaplex-holdings-lawsuit-submission-form?prid=34174&wire=1

According to the filed complaint, (i) macroeconomic pressures and competition in the haircare market were more robust than the Company had represented to investors; (ii) accordingly, the Company was unlikely to maintain its sales and revenue momentum; and (iii) as a result, it was unlikely that the Company would be able to achieve the financial and operational growth projected in the offering documents; and (iv) as a result, the offering documents were materially false and/or misleading and failed to state information required to be stated therein.

Vintage Wine Estates, Inc. (NASDAQ:VWE)

VWE Lawsuit on behalf of: investors who purchased October 13, 2021 - September 13, 2022
Lead Plaintiff Deadline : January 13, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/vintage-wine-estates-class-action-lawsuit-submission-form?prid=34174&wire=1

According to the filed complaint, during the class period, Vintage Wine Estates, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to a material weakness related to its inventory controls and procedures, the Company lacked a reasonable basis to report inventory metrics; (2) the Company understated its overhead burden in certain quarters, thereby overstating its adjusted EBITDA; (3) as a result of the foregoing, Vintage Wine was reasonably likely to incur significant charges to restate prior reporting; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Class Action
Back to newsroom
Back to Newsroom
Share by: